HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TMCI
Treace Medical Concepts, Inc.
TMCI lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TMCI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Weak |
TMCI's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TMCI PE Valuation
TMCI has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TMCI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
TMCI has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over TMCI on earnings, with more consistent year-over-year improvement.
TMCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.85 | -$0.05 |
| Q2 2026 | -$0.92 | -$0.13 |
| Q1 2026 | -$0.96 | -$0.11 |
| Q4 2025 | -$0.93 | -$0.03 |
| Q3 2025 | -$0.80 | +$0.19 |
| Q2 2025 | -$0.79 | +$0.23 |
| Q1 2025 | -$0.85 | +$0.03 |
| Q4 2024 | -$0.90 | -$0.09 |
TMCI is still losing money, but less than at its worst: $0.85 per share over the past year, against $1.02 at its worst in mid-2024.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TMCI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over TMCI on profitability, with a higher operating margin.
TMCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $48.3M | -3.9% |
| Q2 2026 | $45.4M | -4.2% |
| Q1 2026 | $47.2M | -10% |
| Q4 2025 | $62.5M | -9% |
| Q3 2025 | $50.2M | +11% |
| Q2 2025 | $47.4M | +6.6% |
| Q1 2025 | $52.6M | +2.9% |
| Q4 2024 | $68.7M | +10% |
TMCI's revenue has slid since its 2024 peak: $48M last quarter, down 3.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | +7.3 points |
| Q2 2026 | -33% | +2.9 points |
| Q1 2026 | -36% | -6.7 points |
| Q4 2025 | -9.5% | -9.2 points |
| Q3 2025 | -31% | +2.4 points |
| Q2 2025 | -36% | +12 points |
| Q1 2025 | -30% | +7.5 points |
| Q4 2024 | -0.3% | +11 points |
TMCI's operating margin was −24% last quarter, up 7.3 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TMCI on cash generation, producing positive trailing cash flow while its opponent burns cash.
TMCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.4M | +$6.5M |
| Q2 2026 | -$6.9M | +$918K |
| Q1 2026 | $4.2M | +538% |
| Q4 2025 | -$10.4M | -$3.1M |
| Q3 2025 | -$11.9M | +$2.8M |
| Q2 2025 | -$7.8M | +$7.8M |
| Q1 2025 | $655K | +$11.8M |
| Q4 2024 | -$7.3M | -$5.6M |
TMCI has burned cash in almost every quarter: −$19M over the past year, against −$26M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TMCI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TMCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +415K shares |
| 1 year | +3.1% | +1.9M shares |
| 3 years | +6.3% | +3.9M shares |
| 5 years | +24% | +12.7M shares |
| Available history | +49% | +21.6M shares |
TMCI has 65M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TMCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | 36.3x | High |
TMCI's net debt is more than 20 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TMCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.8 | Neutral |
| Stochastic | 57.5 | Neutral |
TMCI's weekly RSI is 65 (neutral) and its Stochastic is 58 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TMCI PE vs Healthcare Sector
TMCI has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TMCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.35 | 23% above |
| 20 week MA | $4.41 | 21% above |
| 50 week MA | $3.22 | 66% above |
| 100 week MA | $5.03 | 6.2% above |
| 200 week MA | $9.47 | 44% below |
TMCI has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TMCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.5 | $17.3 | -32% |
| 2022 | $17.3 | $23.9 | +39% |
| 2023 | $23.9 | $12.8 | -47% |
| 2024 | $12.8 | $6.98 | -45% |
| 2025 | $6.98 | $2.42 | -65% |
| 2026 YTD | $2.42 | $5.34 | +121% |
TMCI has the edge over HIMS on returns for 2026, with the stronger performance.